|Articles|July 19, 2021
Supplements and Featured Publications
- MS Stakeholder Summit: New Treatment Landscape in Multiple Sclerosis (MS)—Preventing Long-Term Disability Through High-Efficacy Treatments in Early MS
New Treatment Landscape in Multiple Sclerosis (MS)—Preventing Long-Term Disability Through High-Efficacy Treatments in Early MS
Advertisement
This AJMC® Stakeholder Summit provides a multistakeholder perspective on opportunities to improve long-term disease outcomes in multiple sclerosis, as well as clinical and payer considerations with early use of high-efficacy therapies.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
4
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making
5
